Topical Versus Injection PRP for Olfactory Dysfunction
NCT07151703 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60
Last updated 2025-09-03
Summary
The goal of this clinical trial is to determine whether two different delivery methods of autologous platelet-rich plasma (PRP) can improve olfactory function in adults with persistent olfactory dysfunction lasting more than three months. The main questions it aims to answer are:
1. Does carrier-assisted topical application of PRP lead to comparable or better improvement in smell function than intranasal injection of PRP?
2. Which method provides greater patient comfort and fewer adverse effects?
Researchers will compare carrier-assisted topical PRP application to intranasal PRP injection to see if one approach is more effective in restoring olfactory function.
Participants will:
1. Receive a single PRP treatment delivered either by injection or via a PRP-soaked carrier placed into the olfactory cleft.
2. Continue daily olfactory training for three months following the intervention.
3. Undergo smell testing (Sniffin' Sticks) before and after treatment and complete quality-of-life questionnaires.
Conditions
- Olfactory Dysfunction
- Anosmia
- Hyposmia
Interventions
- PROCEDURE
-
Intranasal Injection of Autologous PRP
Under topical anesthesia and decongestion, approximately 1 mL of freshly prepared autologous platelet-rich plasma will be injected into multiple sites of the olfactory cleft mucosa bilaterally using a 25-gauge needle under endoscopic guidance. Single treatment session.
- PROCEDURE
-
Carrier-Assisted Topical Application of Autologous PRP
Four pieces of sterile, bioabsorbable carrier (Gelfoam sponge) will be soaked with approximately 5 mL of freshly prepared autologous platelet-rich plasma. Under endoscopic guidance, two pieces will be placed gently into each olfactory cleft, ensuring contact with the olfactory mucosa. Carriers will remain briefly to allow PRP diffusion before dissolving naturally or being removed. Single treatment session.
- COMBINATION_PRODUCT
-
platelet-rich plasma
This study adopts a fully automated, closed-system PRP preparation technique to ensure the stability of the blood product. A total of 60 mL of whole blood is drawn and processed using the Phoenix Q1 centrifuge (TFDA Medical Device Manufacturing License No. 004461) for blood component separation in a closed, sterile environment. An optical sensor identifies and automatically collects the buffy coat layer (rich in platelets and monocytes), yielding approximately 6 mL of autologous platelet-rich plasma (PRP). The centrifugation and PRP collection process takes about 5 minutes. Compared with traditional methods requiring manual identification and collection, this approach enhances the precision and safety of centrifugation-based preparation.
- DEVICE
-
olfactory training
Participants will perform olfactory training for 12 weeks following the PRP intervention. Training is conducted twice daily using four odor bottles containing standardized odorants from Sigma-Aldrich (Germany): lemon (citronellal, #27470), rose (phenylethanol, #77861), clove (eugenol, #W246700), and eucalyptus (eucalyptol, #C80601). Each odor is sniffed gently for about 20 seconds, with a 20-second pause between bottles. Participants will record the perceived intensity of each odor in a training diary after every session.
Sponsors & Collaborators
-
Taipei Veterans General Hospital, Taiwan
lead OTHER_GOV
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-10-01
- Primary Completion
- 2027-12-31
- Completion
- 2028-12-31
Countries
- Taiwan
Study Locations
More Related Trials
-
Subthreshold Laser Treatment for Reticular Pseudodrusen and Geographic Atrophy Secondary to AMD
NCT02800356 ·Status: COMPLETED ·Phase: NA
-
Intravitreal Injection of MSCs in Retinitis Pigmentosa
NCT01531348 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Study to Evaluate Safety and Efficacy of BMMNC in Retinitis Pigmentosa
NCT01914913 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Efficacy of Platelet-rich Plasma (PRP) in the Treatment of Dark Circles Under the Eyes
NCT03114514 ·Status: COMPLETED ·Phase: NA
-
Treatment of Optic Neuropathies Using Autologous Bone Marrow-Derived Stem Cells
NCT02638714 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Pars-plana Vitrectomy vs Panretinal Photocoagulation for Severe NPDR
NCT04103671 ·Status: RECRUITING ·Phase: NA
-
Effects of Subtenon-injected Autologous Platelet-rich Plasma on Visual Functions in Eyes With Retinitis Pigmentosa
NCT04238858 ·Status: COMPLETED ·Phase: NA
-
Safety and Effectiveness Study of 532nm Laser Subthreshold Panretinal Photocoagulation for Severe NPDR
NCT01759121 ·Status: UNKNOWN ·Phase: NA
-
PRP vs PRP+IVC for Severe nPDR
NCT03863535 ·Status: UNKNOWN ·Phase: NA
-
Study to Assess the Efficacy and Safety of Monthly Octreotide Intramuscular Injections in Patients With Proliferative Diabetic Retinopathy After Lasercoagulation This Study is Not Being Conducted in the United States.
NCT00170742 ·Status: TERMINATED ·Phase: PHASE3
-
Microneedle Intra-Arterial Injection for Retinal Artery Occlusion
NCT07151755 ·Status: RECRUITING ·Phase: NA
-
Effectiveness of Plasma Exchange in Treating With Severe Acute AQP4-Ab Positive Optic Neuritis
NCT03586557 ·Status: UNKNOWN ·Phase: NA
-
Safety and Efficacy of Low-Fluence PRP for PDR
NCT01737957 ·Status: TERMINATED ·Phase: NA
-
Clinical Trials of Continuous Oxygen Therapy Combined With Blue Light Deprivation in the Treatment of Retinitis Pigmentosa
NCT02465749 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy
NCT03091569 ·Status: COMPLETED ·Phase: PHASE4
-
Combined Triple Therapy in Diabetic Retinopathy (DRP)
NCT00806169 ·Status: COMPLETED ·Phase: PHASE3
-
Investigating the Structural and Functional Changes to the Retina Following PRP in Diabetic Retinopathy Patients
NCT02621580 ·Status: COMPLETED ·Phase: NA
-
To Evaluate the Efficacy and Safety of Combination Therapy With B55R1 and B55R2 Compared to B55R1 Monotherapy in Patients With NPDR
NCT07230184 ·Status: COMPLETED ·Phase: PHASE4
-
Anti-VEGF Instead of Intraoperative PRP in Proliferative Diabetic Retinopathy
NCT03633266 ·Status: UNKNOWN ·Phase: NA
-
Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration
NCT07266584 ·Status: RECRUITING ·Phase: NA
-
The Therapeutic Effect of Dysthyroid Optic Neuropathy
NCT04096612 ·Status: UNKNOWN ·Phase: NA
-
The Use of Alpha Lipoic Acid for the Treatment and Prevention of Diabetic Retinopathy
NCT01880372 ·Status: TERMINATED ·Phase: NA
-
An Investigator-Initiated Study to Assess the Association of Diabetic Retinopathy Severity Scale (DRSS) With Level of Decreased Corneal Sensitivity
NCT05566717 ·Status: UNKNOWN
-
Subthreshold Laser Treatment Versus Threshold Laser Treatment for Symptomatic Retinal Arterial Macroaneurysm
NCT01301326 ·Status: COMPLETED ·Phase: PHASE3
-
Phase 1 Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa
NCT04925687 ·Status: COMPLETED ·Phase: PHASE1